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dressed each topic with the individual models available to 
answer our questions including animal versus human stud-
ies, pharmacologic, surgical as well as pathophysiologic 
states of acid suppression.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Evidence from comparative anatomy and physiology 
studies indicates that gastric acid secretion developed 
during the evolution of vertebrates approximately 350 
million years ago. The cellular mechanisms that produce 
gastric acid have been conserved over the millennia and 
therefore proton pump inhibitors (PPIs) have pharmaco-
logical effects in almost all relevant species. These obser-
vations suggest that gastric acid provides an important 
selective advantage; however, in modern-day humans the 
need for gastric acid can be been questioned in light of 
the widespread use of safe and effective pharmacologic 
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 Abstract 
 Evidence from comparative anatomy and physiology studies 
indicates that gastric acid secretion developed during the 
evolution of vertebrates approximately 350 million years 
ago. The cellular mechanisms that produce gastric acid have 
been conserved over the millennia and therefore proton 
pump inhibitors have pharmacological effects in almost all 
relevant species. These observations suggest that gastric 
acid provides an important selective advantage; however, in 
modern-day humans the need for gastric acid can be ques-
tioned in light of the widespread use of safe and effective 
pharmacologic acid suppression. The Kandahar Working 
Group addressed questions concerning the need, produc-
tion and effects of gastric acid, specifically: (1) motility in the 
upper gastrointestinal (GI) tract; (2) neuroendocrine factors; 
(3) digestive and mucosal processes; (4) microbiology, and 
(5) central processes and psychological involvement. We ad-
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acid suppression. The Kandahar Working Group ad-
dressed questions concerning the need, production and 
effects of gastric acid, specifically: (1) motility in the up-
per gastrointestinal (GI) tract; (2) neuroendocrine fac-
tors; (3) digestive and mucosal processes; (4) microbiol-
ogy, and (5) central processes and psychological involve-
ment. We addressed each topic with the individual 
models available to answer our questions, including ani-
mal versus human studies, pharmacologic, surgical as 
well as pathophysiologic states of acid suppression.
 Gastric Acid and Motility 
 The effect of gastric acid on gastric motility and emp-
tying has been neglected in the recent literature. More-
over many ‘established facts’ are based on small, short-
term observational studies in healthy volunteers or in 
animal models. Four central issues concerning the inter-
action of gastric acid and function are addressed in this 
review, namely the effects of (1) acid instillation in the 
stomach and small bowel, (2) patho-physiologic states of 
acid secretion, (3) pharmacologic and (4) surgical acid 
suppression.
 Acid Instillation in the Stomach and Small Bowel 
 Early animal studies have shown a dose-dependent 
delay of gastric emptying after instillation of organic ac-
ids (i.e., an inverse relationship between gastric emptying 
rate and hydrogen ion concentration). Increasing the mo-
lecular weight of the organic acids also inhibited gastric 
emptying; however, increasing the instilled volume ac-
celerated the process  [1] . More recently, Holzer et al.  [2] 
confirmed that instillation of physiologic concentrations 
of hydrochloric acid delayed gastric emptying in a rat 
model, an effect that was blocked by atropine, suggesting 
involvement of a vagal mechanism.
 The effects of small bowel acid exposure on gastric 
emptying are also inhibitory. Lin et al.  [3] used a dog 
model in which they exposed different lengths of small 
bowel with different concentrations of acid. A dose-de-
pendent inhibition of gastric emptying was demonstrat-
ed. This effect increased as longer segments of small bow-
el were exposed to acid; however, no effect was observed 
beyond the proximal 150 cm of jejunum. Other authors 
reproduced these findings and demonstrated that vagot-
omy attenuates the effects of gastric acid instillation on 
motility  [4] .
 Although acid receptors in the stomach may inhibit 
gastric emptying directly, these studies suggest that the 
inhibitory effect of acid on gastric emptying is mediated 
by pH receptors in the proximal small bowel  [4, 5] . This 
effect probably serves to maintain neutral pH for efficient 
small bowel digestion. Given the large volume of gastric 
acid secretions (1.5–2.5 liters/day), efficient feedback 
mechanisms are mandatory to ensure effective buffering 
of acid leaving the stomach and the appropriate interac-
tion between gastric and small bowel function.
 Pathophysiologic States of Acid Secretion 
 It has been shown that gastric emptying is delayed in 
patients with atrophic gastritis compared to healthy con-
trols  [6] . In this condition plasma levels of gastrin are in-
versely related to gastric emptying and, consistent with 
this finding, patients with residual acid secretion have 
faster emptying rates than those with achlorhydria  [6] . 
However, the effect of gastrin on gastric function is not 
straightforward because in patients with chronic hyper-
gastrinemia, such as the Zollinger-Ellison syndrome, no 
consistent changes in gastric emptying are seen  [7] . This 
paradox may be explained by the effect of gastrin on se-
cretion volume. Classic studies by Hunt and Stubbs  [8] 
have shown that large volumes empty from the stomach 
faster than small volumes. In atrophic gastritis elevated 
levels of gastrin represent a feedback response to de-
creased gastric secretion from diseased mucosa, whereas 
in Zollinger-Ellison syndrome pathological levels of gas-
trin from a neuroendocrine tumor drive excessive gastric 
secretion. Thus, in these pathophysiologic states, the ef-
fect of gastrin on gastric emptying may be counteracted 
by changes in gastric secretion volume. This explanation 
is supported by a study that showed that replacement of 
gastric secretions (including acid and pepsin) normalized 
emptying and improved trituration of solid foods in pa-
tients with atrophic gastritis  [9] .
 Pharmacologic Acid Suppression 
 In the fasted state, acid suppression increases phase 3 
migrating motor complex (MMC) activity (‘housekeep-
ing contractions’ that clear the bowel of undigested de-
bris), whereas stimulating gastric acid secretion decreas-
es MMC activity  [10, 11] . This is likely due to alkaline pH 
in the duodenum triggering this contraction pattern 
 [10] .
 In the fed state, most (but not all) studies show that 
acid suppression with H 2 -receptor antagonists (H 2 RA) 
and PPIs delays gastric emptying of solid food, although 
effects on liquid food are less consistent  [9, 12–15] . Inter-
estingly the delay in solid emptying is associated with 
vigorous antropyloroduodenal (APD) contractions (with-
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out a change in peristaltic frequency)  [16] . It has been sug-
gested that the combination of increased APD activity 
and delayed gastric emptying indicates poor coordina-
tion of antral contraction with pyloric opening. However, 
it is also possible that acid suppression impairs chemical 
digestion and more vigorous mechanical breakdown of 
solid foods is required before gastric contents can pass 
through the pylorus  [9, 17] . As in atrophic gastritis, phar-
macologic acid suppression leads to hypergastrinemia 
 [18, 19] . Studies have shown that intravenous infusion of 
gastrin increases antral activity and delays gastric empty-
ing  [16] . Moreover reduced gastric secretion volume on 
H 2 RAs or PPIs would also be expected to slow gastric 
emptying  [11] . However, the relative importance of acid 
suppression on secretion volume and motility with re-
gard to gastric emptying is unknown.
 Surgical Acid Suppression 
 In contrast to pharmacologic acid suppression, the ef-
fects of highly selective vagotomy on the gastric body
(i.e., denervating the parietal cells but sparing the pylo-
rus) in patients with peptic ulcer disease has been subject 
to long-term follow-up with regards to gastric motility 
and acid suppression  [20–22] . Delayed gastric emptying 
is common in the early post-operative period; however, 
gastric function normalizes in the majority of patients at 
repeat testing after 6–12 months  [20, 21] , an effect that is 
maintained for at least 10 years despite a sustained reduc-
tion in basal and stimulated acid output  [22] .
 Summary 
 Gastric acid has effects on upper GI functions in ani-
mal models and healthy volunteers. Acid-sensitive recep-
tors provide feedback regulation that prevents the pas-
sage of excess gastric acid into the small bowel and main-
tains a pH environment conducive to efficient digestion. 
In disease states as well as pharmacologic studies, re-
duced acid secretion appears to delay gastric emptying; 
however, it is difficult to differentiate the effects of secre-
tion volume and acid production on this process, and the 
clinical importance of this observation remains uncer-
tain. Firstly, it has not been established that this effect is 
associated with symptoms of gastric retention or clini-
cally relevant maldigestion. Secondly, no long-term fol-
low-up data has been published. Although surgical pro-
cedures such as highly selective vagotomy may have di-
rect effects on gastric function that delay emptying, it is 
interesting to note that these return to normal within a 
year. Thus, at least in the post-operative state, there ap-
pear to be compensatory mechanisms that can normalize 
gastric emptying despite a sustained reduction in gastric 
acid secretion. Similarly, the effects on gastric emptying 
and motility are reproducible in different states of acid 
suppression but have not been shown to be clinically rel-
evant and seem to be compensated in the mid- to long-
term. Further studies are required to address whether pa-
tients experience symptoms directly or indirectly related 
to delayed gastric emptying during pharmacologic acid 
suppression, and to assess whether gastric function re-
turns to normal over time.
 Neuroendocrine Regulation of Gastric Acid 
Secretion 
 Cranial, Gastric and Postgastric Secretory Responses 
 Gastric acid secretion is subject to a complex regula-
tion by endocrine, paracrine and neurocrine mediators 
that interact extensively. Even before ingestion, the sight 
and smell of food leads to acetylcholine release from vagal 
nerve fibers that stimulates acid production via stimula-
tion of M 3 receptors on parietal cells and also, indirectly, 
by increasing histamine release via acetylcholine recep-
tors on the surface of ECL cells. Intragastric distension 
and an increase in luminal pH, together with certain nu-
tritional factors (e.g., calcium), further promote gastric 
acid secretion via release of gastrin from antral G cells. 
Gastrin mediates its stimulatory action on parietal cells 
mainly via the blood stream and induction of histamine 
release from ECL cells in the proximal stomach, but also 
has a direct stimulatory effect on parietal cells via chole-
cystokinin (CCK-B) receptors. This alternative pathway 
is probably of minor physiological importance. The most 
important physiological inhibitor of gastric acid secre-
tion is somatostatin secreted by antral D cells in response 
to low intraluminal pH. This inhibits gastrin release and 
gastric acid secretion directly via receptors on parietal 
cells and indirectly by inhibiting histamine secretion 
from ECL cells. In humans CCK is a potent stimulant for 
somatostatin release acting via CCK-A receptor, thereby 
inhibiting gastrin secretion  [23] . Another potent inhibi-
tor of gastric acid secretion is secretin. Its release is stim-
ulated by duodenal acid and the effect is also mediated 
mainly by somatostatin  [24, 25] . Numerous other neuro-
hormonal peptides involved in the GI response to feed-
ing, including GIP, GLP-1, GLP-2, PYY, VIP, galanin and 
GRP also regulate gastric acid secretion via actions on 
gastric G, ECL and D cells, respectively  [26–33] .The ef-
fects are largely inhibitory and exerted via central feed-
back.
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 The Effect of Ghrelin on Gastric Secretion 
 This review focuses on the effects of recently discov-
ered enterohormones on gastric acid secretion, in particu-
lar ghrelin, an orexigenic peptide produced to 80% by the 
gastric oxyntic mucosa (X/A cells), but to a minor degree 
also in the central nervous system  [34, 35] . Ghrelin accel-
erates gastric emptying in experimental animals and hu-
mans by inducing ‘fasting’ type 3 MMC activity  [36] . The 
role of ghrelin in the regulation of gastric acid secretion
is accepted; however, interpretation of findings is diffi-
cult as its effects are dose dependent and vary with the 
mode of delivery  [37–44] . Following intravenous ap pli-
cation [5–20   g/kg ( , 1.5–6 nmol/kg), molecular weight 
of ghrelin: 3,314 g/mol]  in rats, stimulation of gastric acid 
secretion was observed which was almost equipotent to 
histamine (3 mg/kg i.v.). The anticholinergic atropine and 
cervical vagotomy, but not an H 2 -receptor antagonist in-
hibited this effect  [40] . Similarly, whereas relatively low 
doses of intraperitoneal ghrelin [5–80   g/kg ( , 1.5–24 
nmol/kg)] increase gastric acid output  [43] , high doses of 
ghrelin (1–30 nmol/kg i.v.) given to rats with chronic gas-
tric fistula or subcutaneously (1–10 nmol/kg) had either 
no effect on gastric acid output or inhibited acid output 
 [41] . The central effects of intracerebroventricular ghrelin 
on gastric acid secretion are dose dependent and inhibi-
tory at low doses (0.1 pmol/rat to 1 nmol/rat, maximum 
effect: 1 pmol/rat) in conscious rats, suggesting a tonic in-
hibitory role of ghrelin in the central control of gastric 
secretion  [38] . Conflicting results reported in urethane-
anesthetized rats during intracerebroventricular applica-
tion of ghrelin (0.3, 0.6 or 1 nmol/rat)  [42] may be due to 
the effects of urethane on somatostatin release or, once 
again, to higher dosages used in the latter study. Taken 
together, peripheral application of low doses of ghrelin 
stimulated gastric secretion in most studies while higher 
doses had no or even inhibitory effects. In contrast, cen-
tral application of ghrelin in conscious rats inhibited acid 
output at very low doses, higher doses had less impact or 
resulted in stimulation. An intact vagal system was essen-
tial for mediating central and peripheral effects  [40, 42, 
44] . The apparently discrepant impact of peripheral and 
central ghrelin at various doses may be explained by the 
existence of different receptor subtypes: two isoforms 
have been identified, the predominantly central GHS-R 1a 
receptor and the GHS-R 1b receptor prevalent in the hu-
man fundus and antrum. The latter was thought to be 
inactive  [45, 46] but has been attributed biological activ-
ity by recent authors  [47, 48] . Cell culture experiments 
suggest that a further, unidentified subtype, or even sub-
types, of ghrelin receptor also exists  [46] .
 The following hypothesis could explain the observa-
tions described above. Central ghrelin exerts a (tonic) in-
hibitory control of gastric acid secretion via GHS-R 1a re-
ceptors at very low levels. Low levels of peripheral ghrelin 
release stimulate gastric acid secretion via GHS-R 1b re-
ceptors or an as yet unidentified novel receptor subtype. 
As ghrelin is produced in the stomach, additional activa-
tion of central GHS-R 1a receptors reverses the stimula-
tory effect. It has been observed that peripheral adminis-
tration of ghrelin compared with intracerebroventricular 
application allows only limited access of the compound 
to hypothalamic sites. This may explain why high periph-
eral ghrelin concentrations are needed to induce inhibi-
tion  [39] . Thus, under physiological conditions, the post-
prandial decrease in ghrelin plasma levels may release the 
inhibitory effect of central ghrelin and promote gastric 
acid secretion. It has to be emphasized that this scheme is 
based on the findings of animal studies as there have been 
no human studies on the effects of ghrelin on gastric acid 
secretion.
 Other Recently Discovered GI Peptide Hormones 
 Amylin, a 37-aa peptide that shows 50% homology 
with the calcitonin-gene-related peptide, is colocalized 
with somatostatin in endocrine cells of the gastric fundus 
 [52] and released in response to meal ingestion. Endoge-
nous amylin stimulates somatostatin secretion via an au-
tocrine pathway, resulting in an inhibition of histamine 
and acid secretion  [53] . Adrenomedullin, another mem-
ber of the calcitonin family, is localized in ECL and chief 
cells in the oxyntic mucosa. Similar to amylin, it stimu-
lates somatostatin secretion and thus inhibits histamine 
and acid secretion  [54, 55] . Different to amylin, the effect 
appears to be mediated via activation of intramural gas-
tric fundic neurons since it is abolished by the axonal 
blocker tetrodotoxin  [55] . The neuropeptide pituitary ad-
enylate cyclase-activating peptide, which belongs to the 
glucagon/VIP family, stimulates both release of hista-
mine from ECL cells and somatostatin release  [56–58] . 
The resulting effect on gastric acid secretion is discussed 
inconsistently in the literature and depends on the spe-
cies and experimental model used.
 Summary 
 The control of gastric acid secretion depends on the 
central and peripheral effects of neuroendocrine hor-
mones mediated directly and via vagal activity on the 
stomach. The initial cephalic and gastric response is pre-
dominantly stimulatory to gastric digestion, whereas the 
postgastric effects are inhibitory to maintain the correct 
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intestinal pH for intestinal digestion. Numerous neuro-
hormones have been attributed to play a part in the regu-
lation of gastric acid secretion. Whereas gastrin, CCK 
and GLP-1 together with the more recently discovered 
GLP-2 are known to regulate gastric acid production, 
ghrelin and amylin yield dose- and application-depen-
dent changes too inconsistent to clearly establish their 
role and human studies are largely unavailable.
 Gastric Acid and Digestive and Mucosal Processes 
 Calcium Absorption 
 The dissociation of food calcium complexes and the 
liberation of Ca 2+ from calcium salts is strongly depen-
dent on pH. This has led to the assumption that the pres-
ence of gastric acid is a necessary prerequisite for intesti-
nal Ca 2+ absorption. The negative effect of gastrectomy 
 [59–61] or pernicious anemia  [62] on bone mass supports 
this hypothesis. Moreover, a recent epidemiological study 
in patients older than 50 years revealed an increased risk 
of hip fracture in patients on long-term PPI  [63] . Calcium 
is absorbed by two mechanisms: solubilization and con-
version into its ionized form (Ca 2+ ) is efficient at low gas-
tric pH and active absorption occurs in the duodenum 
and jejunum  [64–67] . Passive calcium uptake occurs pre-
dominantly in the distal intestine and can compensate 
deficits in the active absorption pathway with high oral 
calcium uptake. Animal studies have yielded conflicting 
results regarding the influence of gastric acid on Ca 2+ ab-
sorption, and some suggested normal overall Ca 2+ intake 
at high oral intake even after complete suppression of gas-
tric acid secretion  [68, 69] . However, recent trials in hu-
mans, including both normal subjects and high-risk pop-
ulations (postmenopausal women, patients on dialysis) 
showed that the oral application of calcium results in a 
serum peak of ionized as well as protein-bound calcium, 
which is missing in the presence of a complete blockade 
of gastric acid  [70–72] . Furthermore it has been shown 
that the total intestinal calcium resorption was signifi-
cantly reduced in postmenopausal women during high-
dose PPI intake  [73] . Gastrectomized rats rapidly lose 
bone mass  [74–77] , and in humans, gastrectomy also leads 
to osteopenia. The pathophysiology is multifactorial and 
may include hypergastrinemia, malabsorption, lack of ox-
yntic mucosa, vagal dysregulation with a disturbance of 
the gastrin-parathyreoid axis, and bacterial overgrowth. 
But also non-resective operations, like supraselective va-
gotomy, or disease, like pernicious anemia, result in os-
teopenia and an increased bone turnover.
 In addition to reducing calcium absorption by inhibit-
ing gastric acid, experimental studies have demonstrated 
that the inhibition of proton pump activity in osteoclasts 
has direct inhibitory effects on bone resorption and re-
lease of bone calcium  [78, 79] . Although this effect may 
be discussed as a protective direct effect on bone tissue, 
it could further impair calcium metabolism and is an-
other mechanism by which PPIs might contribute to the 
increased risk of hip fractures in elderly patients  [63] . 
These patients require careful review as to their need for 
oral Ca + supplements and other forms of osteoporosis 
prophylaxis.
 Hematinic Absorption 
 Dietary iron, present in food as either heme iron or 
non-heme iron, is absorbed predominantly in the duode-
num. Acid is important for solubilization, reduction and 
subsequent absorption of dietary iron. Decreased absorp-
tion has been reported in patients with hypochlorhydric 
conditions, such as gastrectomy, vagotomy, multifocal 
atrophic gastritis and autoimmune gastritis. Therefore, 
clinical monitoring of anemia and iron levels in gastrec-
tomized patients or during long-term acid secretion seem 
reasonable  [80–87] .
 Hypochlorhydria affects also the absorption of vita-
min B 12 (cobalamin)  [88–92] . The vitamin is protein 
bound and is released in the presence of acid and pepsin. 
Vitamin B 12 is subsequently bound to haptocorrins and 
passes into the small intestine. There cobalamin is liber-
ated by pancreatic proteases and bound to intrinsic fac-
tor, which protects the vitamin from catabolism by in-
testinal bacteria. Intrinsic factor also mediates the ab-
sorption in the terminal ileum. Reduced cobalamin 
assimilation has been observed in patients with chronic 
gastric hyposecretion, such as during chronic atrophic 
gastritis  [93–96] , long-term therapy with PPIs  [90] and 
after vagotomy  [92, 97] . Especially subsets of  Helico-
bacter-pylori -infected persons have an increased risk to 
develop cobalamin deficiency. It remains unclear wheth-
er this is a direct effect of hypochlorhydria or indirect via 
small intestinal bacterial overgrowth. Nevertheless, peri-
odic assessment of cobalamin levels has been recom-
mended for patients on chronic anti-secretory therapy 
 [90] . Patients with pernicious anemia have a normal life 
span on B 12 substitution therapy  [98] .
 Protein and Lipid Metabolism 
 Acid secretion from gastric parietal cells facilitates 
protein and lipid digestion  [99] . Pepsinogen, the most po-
tent protease, is produced in gastric chief cells and is ac-
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tivated under acidic conditions below a pH level of 4. Un-
der hypochlorhydric conditions, impaired digestion of 
proteins occur and malabsorption of proteins has been 
observed  [100, 101] , although muscular atrophy or weight 
loss are rare. In addition, small intestinal bacterial over-
growth in hypochlorhydria probably leads to reduced 
breakdown of the metobolically useful products of pro-
tein and lipid digestion, thereby reducing their availabil-
ity for certain essential amino and fatty acids (e.g., tryp-
tophan, tyrosine and arachidonic acid). This effect has 
been suggested as a precipitating factor for depression 
(tryptophan is a precursor of serotonin) and other health 
problems in hypochlorhydric patients  [89] .
 Differentiation and Regeneration of the Mucosal 
Epithelium 
 The differentiation of the gastric epithelium depends 
on the presence of gastric acid. The human epithelium in 
the GI tract belongs to the most quickly regenerating tis-
sues in the body. All types of stomach epithelial cells are 
derived from a single progenitor cell in each gland. These 
stem cells are able to divide and to proliferate continu-
ously. In mice (HK-ATPase knock-outs) or rats artificial-
ly depleted of gastric acid (gastrectomy), the normal dif-
ferentiation process is disturbed so that metaplastic cells 
arise and gastric function is altered  [74–76] . The presence 
of acid affects the healing of ulcers and regeneration. Ar-
tificial ulcers generated in rats lead to the release of 
growth factors at the topical site of the mucosa. Several of 
the growth factors, such as the hepatocyte growth factor, 
are activated only in acidic milieu, and ulcer healing is 
paradoxically prolonged in the absence of acid in animal 
models  [102] .
 The data concerning tissue differentiation and regen-
eration are contradictory. Gastric-acid-activated gene ex-
pression of CDx2 in cellular models such as keratinocytes 
leads to metaplasia, similar to the development of special-
ized intestinal metaplasia in the distal esophagus, i.e., 
Barrett’s esophagus  [103–107] . However, absence of acid 
in mouse models may also lead to the differentiation of 
parietal cells into a pre-parietal and metaplastic state, not 
able to express HK-ATPase. Long-term acid suppression 
increases gastric metaplasia type II and atrophy, especial-
ly in the presence of  H. pylori; however, these cells appear 
to represent a de-differentiated state and long-term fol-
low-up studies have not demonstrated an increased risk 
of gastric cancer  [106, 108] . Nevertheless it is recom-
mended that  H. pylori is eradicated from patients requir-
ing long-term acid suppression.
 Summary 
 Gastric acid affects the solubilization, digestion and 
absorption of several key nutrients. The importance of 
acid secretion is not critical under physiological condi-
tions in patients taking a normal western diet; however, 
pathologic conditions including chronic gastric inflam-
mation, gastric atrophy and hypochlorhydria help reveal 
the contributory role of gastric acid. The need for calci-
um, iron and vitamin supplements should be monitored 
during long-term PPI treatment in high-risk patients, 
such as postmenopausal women. Long-term acid sup-
pression can also lead to mucosal gastric metaplasia and 
atrophy. Although the risk of gastric carcinoma is not el-
evated, it seems reasonable to manage other risk factors 
(e.g.,  H. pylori ) that may exacerbate these effects.
 Gastric Acid, GI Flora and Infection 
 GI Flora 
 Ingestion of food and fluids via the oral route intro-
duces bacteria and other microorganisms into the esoph-
agus and upper GI tract. Disinfection of this material has 
been suggested as a major role for gastric acid, as both the 
stomach and the proximal small intestine are virtually 
free of bacterial pathogens  [109] . If this role of gastric acid 
is so important, reduction or elimination of gastric acid 
should alter the flora of the stomach and small intestine.
 Stomach 
 The acid environment of the stomach is a filter for bac-
teria from the oropharynx and from the swallowed food 
and drinks. Thus it is difficult to distinguish whether bac-
teria found in the stomach really colonize the stomach or 
whether these are transients. A recent genomic character-
ization of the gastric flora yielded 128 different strains of 
bacteria, 13 of which have not been characterized in vivo 
 [110] . There is a relationship between gastric luminal pH 
and the number of organisms in diseases with reduced acid 
secretion  [111–113] and during acid-suppression therapy 
 [114–117] . This change seems to be dependent on the 
amount of gastric acid suppression as the increase in bac-
teria is greater with PPI than with H 2 -RA  [118–120] . Pa-
tients on acid suppression due to gastroesophageal reflux 
disease (GERD) treated with either PPIs or H 2 -RAs have a 
similar prevalence of  H. pylori but a higher prevalence of 
non- H. pylori bacteria than controls in gastric juice aspira-
tions (61 and 60% vs. 29%, respectively). They are mostly 
oropharangeal species and very rarely anaerobic  [120] . In 
a systematic review  [121] , there was an increase of bacteria 
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in gastric juice in 12 out of 13 studies, irrespective of the 
investigated drug, either H 2 -RAs (cimetidine, ranitidine) 
 [122–132] or PPIs (omeprazole)  [118, 133–139] . Growth at 
the mucosal surface may be detected in about 50% of pa-
tients after long-term treatment with any type of effective 
antisecretory drug  [119, 140] . There have been concerns 
that these bacteria may produce carcinogenic nitrosa-
mines and increase the risk of gastric cancer, although 
there is no evidence that acid suppression increases nitro-
samine production  [119, 140] . This could be explained by 
the fact that bacterially produced nitrosamines are at least 
partly dependent on acid catalyzation, a chemical process 
which occurs optimally at a pH of 2. In contrast, acid sup-
pression may decrease nitrosamine production, which 
could be most relevant at the gastro-esophageal border and 
cardia  [141, 142] .
 The disease state of atrophic gastritis is associated 
with complete achlorhydria; however, also other secre-
tory products (e.g., pepsinogen) are eliminated. In pa-
tients with atrophic gastritis there is a significant increase 
in total bacterial count of the gastric lumen, with pre-
dominantly coliform bacteria  [143] , but no data on the 
clinical consequence of these changes are currently avail-
able. Similarly an increase of coliform bacteria is ob-
served after partial gastric resection and gastroenteros-
tomy  [143] . However, the postoperative changes of bar-
rier function and motility changes are fundamental, so 
they cannot be attributed to changes in gastric acid secre-
tion alone.
 In summary, both the contamination of the gastric 
juice and the colonization of the gastric mucosa with 
non- H. pylori flora increased during long-term acid inhi-
bition and they seem dependent on length and extent of 
acid elimination, the clinical significance of which re-
mains to be determined  [144] .
 Modulation of Acid Secretion by  H. pylori and Risk 
of Intestinal Infection 
 H. pylori has been shown to modulate gastric acid se-
cretion. However, the pattern in which modulation of 
acid secretion occurs varies from patient to patient. In 
 Helicobacter -associated gastritis and  H. pylori -associated 
duodenal ulcers increased acid secretion is found. It has 
been speculated that this is due to increased release of 
gastrin and diminished mucosal expression of soma-
tostatin  [145] . Bacterial products recognized via pattern 
recognition receptors and pro-inflammatory cytokines 
such as TNF  are likely to cause these changes. In gastri-
tis involving the gastric corpus acid secretion is decreased 
 [146] . The  H. pylori -induced decrease of acid secretion 
has been reported to be moderate: a 24-hour intragastric 
pH monitoring showed an increase in pH in patients 
without  H. pylori infection from 1.4  8 0.1 to 1.6  8 0.3 in 
patients with  H. pylori infection (median  8 SD; p  ! 0.01) 
 [147] .  H. pylori -associated mucosal atrophy may also con-
tribute to reduced acid secretion; however this has not 
been correlated in detail.
 Investigations whether  H. pylori -associated decrease 
of gastric acid secretion increases the risk of typhoid fever 
did not show a causative role but a common risk of envi-
ronmental exposure to both bacteria, e.g., poor hygiene 
 [148] . In a similar study on the risk of cholera infection, 
the authors reported that the overall risk of cholera was 
not significantly increased among  H. pylori -infected sub-
jects; the risk of cholera of life-threatening severity, how-
ever, was significantly elevated  [149] . It again is unclear 
whether suppression of acid secretion contributes to the 
risk of more severe cholera as the overall risk is not in-
creased, which should be the case if an  H. pylori -induced 
rise in gastric pH would predispose to more intestinal in-
fections in general.
 Small Intestine 
 There is evidence that continuous acid-suppression 
therapy can lead to bacterial overgrowth in the small in-
testine  [150] . In a controlled prospective study, duodenal 
juice was obtained from patients on continuous 6-week 
PPI therapy and compared to controls. No patient in the 
control group had duodenal bacterial overgrowth, while 
in the omeprazole group bacterial overgrowth was found 
in 14 (56%) patients, and the number of bacteria in the 
duodenal juice of patients treated with omeprazole was 
distinctly higher compared with the control group. Be-
sides bacteria from the oral cavity, fecal-type bacteria 
were present in 7 of 14 and anaerobic bacteria in 3 of 14 
patients; however, there was no apparent sign of clinical 
side effects or significant consequences of duodenal bac-
terial overgrowth  [150] . In a subsequent prospective ran-
domized study these effects were more marked in pa-
tients on omeprazole compared with patients on cimeti-
dine. Moreover, gastric pH was higher in patients with 
bacterial overgrowth compared with those without; find-
ings that support the contention that the incidence of gas-
tric and duodenal overgrowth is dependent on the level 
of acid suppression.
 GI Infections 
 Stomach 
 It is well known that some enteric pathogens are more 
acid-resistant than others.  Escherichia coli  and  Shigella 
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flexneri can both survive exposure to a pH of 2.0  8 2.5, 
whereas  Salmonella enterica typhimurium  is killed fol-
lowing exposure to pH 3. The ability to survive at a low 
pH is thought to be one factor that determines the infec-
tive dose required to cause disease  [121] . From these ob-
servations it has been concluded that the presence of gas-
tric acid has important implications for the survival of 
pathogens that have entered the GI tract. Suppression of 
gastric acid secretion may allow infection to occur fol-
lowing ingestion of a smaller number of inoculated patho-
gens such as  Salmonella enterica or  Listeria monocyto-
genes  [131, 137, 151] . There is some evidence to support an 
increased risk of parasitic infections under conditions of 
reduced acid secretion  [151–153] . Whether there is an in-
creased risk of viral or bacterial gastroenteritis in patients 
receiving gastric-acid-suppression therapy remains con-
troversial  [154] . Neal and coworkers  [155, 156] performed 
a case-control study that found omeprazole treatment in 
the month before infection to be associated with a 10-fold 
increased risk of  Campylobacter infection. Canani et al. 
 [157] also investigated the frequency of gastroenteritis 
among children on gastric-acid-suppression therapy. 
They showed that subjects using acid-suppressing drugs 
were more likely to have acute gastroenteritis (OR 3.58; 
CI 1.87–6.86) than matched controls. No differences were 
observed between H 2 blocker and PPI users in acute gas-
troenteritis.
 Small Intestine 
 Gastric surgery is associated with increased rates of 
intestinal infections. The first report on salmonellosis 
following gastric surgery was of 9 cases of  S.  enterica  t. 
 infection published in the  New England Journal of Medi-
cine in 1956  [158] . A larger study comparing 277 patients 
with salmonella infection with 436 patients admitted to 
an infectious disease hospital suffering from other infec-
tions revealed a significantly higher number of cases of 
gastric surgery in the salmonella-infected group than in 
the control group. This was confirmed by a case-control 
study of laboratory-confirmed patients with a  S. enterica 
infection with well-matched controls. Use of both H 2 an-
tagonists and PPIs were associated with a 4-fold increased 
risk of endemic  S. enterica enteritidis infection. PPIs were 
also linked to an 8-fold risk of endemic  S. enterica t. in-
fection; however, colonization with these bacteria had no 
clear clinical consequences  [160] . A retrospective case-
control study found an increased risk of  Clostridium dif-
ficile diarrhea under current use of PPI therapy  [161] . 
Similar results were obtained in a case-control study us-
ing a United Kingdom clinical research database. Expo-
sure to a PPI in the 90 days before the index date of the 
study was associated with a 2- to 3-fold increased risk of 
 C. difficile -associated diarrhea  [162–164] .
 With respect to  Campylobacter jejuni infection, no as-
sociation with acid suppression in a large prospective 
case-control study has been shown. Of the risk factors 
foreign travel, living on a farm, taking antibiotics or ant-
acids, and having problems with rodents or houseflies in 
the home, only living on a farm was associated with ill-
ness (OR 2.484; 95% CI 1.041–5.930)  [165] .
 Summary 
 There has been growing attention to effects of acid-
suppression therapy on gastric microbiology: gastric acid 
suppression leads to a quantitative increase and change 
of the gastric flora dependent on length and extent of acid 
suppression, which seems not to be translated into symp-
toms or changes in small intestinal absorptive function. 
However, there is growing evidence for an increased risk 
of bowel infection in states of chronic gastric acid sup-
pression that may influence treatment decisions in cer-
tain situations.
 Gastric Acid and Hunger, Satiation and Mood 
 Central and Peripheral Control of Gastric Secretion 
 The central nervous system has an important role in 
the regulation of gastric acid in primates. Sham feeding 
studies show that up to 50% of gastric acid secretion oc-
curs during the cephalic phase of feeding  [166] . This ef-
fect is mediated primarily by the vagus nerve directly or 
indirectly via release of various peptide hormones. The 
prosecretory influence of the central nervous system on 
gastric acid secretion is effectively blocked by sub-dia-
phragmatic vagotomy. Interestingly it was demonstrated 
that, in addition to well-known peptide hormones such 
as gastrin and somatostatin, recently discovered peptides 
such as ghrelin also modulate acid secretion  [43] . The 
main source of gastrin and ghrelin is the gastric mucosa 
 [167, 168] ; however, both are also produced by the hypo-
thalamus  [34, 169] .
 Interaction between Control of Gastric Secretion and 
Feeding Behavior 
 Gastrin tends to reduce feeding behavior in animal 
models  [170] , whereas ghrelin stimulates hunger and in-
creases nutrient intake in various species  [171] , including 
humans  [172] . Considered together these observations 
raise the question whether mechanisms that control gas-
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tric acid secretion have a direct influence on hunger, sa-
tiety and feeding behavior and thus on body weight. 
Moreover, given the close anatomical relationship of 
feeding centers and emotional centers in the hypothala-
mus and limbic system, it could be envisaged that modu-
lating gastric acid secretion could have effects on emo-
tional well-being. Information concerning these possi-
bilities is very limited. Campbell et al.  [170] investigated 
the effects of proton pump (H + /K + -ATPase) inhibition by 
omeprazole on feeding behavior in hens. In addition to 
reduced gastric acid secretion, a reduction in energy in-
take was also observed. In these animal experiments, the 
reduction in feeding was attributed to the rise in gastrin 
levels with PPI inhibition by omeprazole  [170] . Surpris-
ingly, no similar experiments or observations have been 
reported in humans. What is established in humans is 
that underweight, malnourished patients have low levels 
of gastric acid secretion, whereas obese patients have a 
raised maximal secretory capacity (peak acid output) but 
normal basal acid output  [117, 173, 174] . Studies in pa-
tients having had gastric banding surgery for morbid 
obesity have shown that peak acid output is significantly 
reduced following weight loss, whereas basal acid output 
is unchanged  [175] . Together these observations suggest 
a link between body weight and acid secretion. Severe 
malnutrition is associated with parietal cell dysfunction, 
which may be the decisive control mechanism by which 
nutritional state influences gastric acid secretion. These 
findings provide interesting insights into the effect of 
feeding behavior, body weight, changes in body weight 
and gastric acid secretion. Nevertheless, despite the large 
number of clinical trials that involve PPIs, there is no 
clear link between gastric acid inhibition and feeding be-
havior or body weight. This could be due to the interac-
tion between gastric acid production reflux symptoms 
and feeding behavior (e.g., reducing gastric acid produc-
tion increases gastrin, which might inhibit food intake 
but reduces reflux symptoms that could well increase 
food intake).
 Gastric Secretion and Psychological State 
 A related question is whether the presence or absence 
of gastric acid has a meaningful effect on mood or emo-
tional state. Possible models that could help address this 
question include the study of conditions that are linked 
to reduced gastric acid secretion (atrophic gastritis, va-
gotomy, PPI therapy) and those in which gastric acid se-
cretion is increased (Zollinger-Ellison syndrome, peptic 
diseases of the upper GI tract). Before the discovery of  H. 
pylori, a number of attempts were made to establish a link 
between personality or emotional affect and peptic ulcer-
ation  [176] . It was proposed that an elevated level of anx-
iety in patients with duodenal ulceration could lead to 
increased gastric acid production  [177] . However, it was 
shown that although neuropsychological factors such as 
fear, stress and conflict did have effects on gastric acid 
production in healthy volunteers, the hypergastrinemia 
in peptic ulcer disease was independent of emotional 
state  [178] . Moreover, it is possible that the characteristic 
‘ulcer personality’ described in the literature is an effect 
rather than a cause of the disease  [179] . New investiga-
tions in patients with GERD have revealed a further as-
pect of the relationship between stress, GI symptoms and 
disease: stress increases visceral sensitivity and the asso-
ciation between reflux events and symptoms  [180] . On 
this basis it has been shown that symptoms associated 
with GERD can be reduced by relaxation training  [181] . 
However, external stressors do not increase acute gastric 
acid secretion  [182] .
 Very little data exist regarding the central perception 
of gastric acid and influence on affect or mood. Kern et 
al.  [183] were able to show that, even below the conscious 
perception threshold, esophageal acid exposure leads to 
a rapid and intense cortical activation in GERD patients 
and healthy volunteers. This raises the question of how a 
potentially painful stimulus such as acid is perceived in 
gastrointestinal disease. Centrally active mediators that 
may play a role in this process include corticotropine-
releasing hormone, 5-HT 3 -receptor-ligands, melatonin 
und dopamine  [184–187] , all of which are thought to play 
a role not only in the response to pain and other stressful 
stimuli but also in psychological state. Epidemiological 
studies provide further evidence of the link between af-
fective disorders and changes in gastric acid secretion 
and peptic ulcer disease: a Canadian study revealed that 
patients receiving antidepressant therapy had an in-
creased usage of PPIs  [188] . Moreover, a high percentage 
of patients with bipolar disorder have circulating anti-pa-
rietal antibodies  [189] ; however, it remains unclear wheth-
er these patients also have atrophic gastritis or hyposecre-
tion of gastric acid.
 Summary 
 There is little evidence for involvement of gastric acid 
or its suppression in sensation of hunger, satiation or 
mood. In animal models caloric intake was shown to be 
reduced under acid-suppression therapy; however, no 
clear link between acid suppression and changes in feed-
ing behavior or body weight has been established. Gastric 
acid production may be acutely increased by neuropsy-
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chological factors such as anxiety or fear; however, in 
peptic ulcer disease it is independent of the emotional 
state. The characteristic ‘ulcer personality’ described in 
the literature may therefore be an effect rather than a 
cause of the disease. Future directions of studies will in-
clude not only the effects of gastric acid secretion on per-
ception, mood and emotion, but also whether anti-secre-
tory therapy has effects on central processes and how 
these are mediated. Early evidence that supports central 
effects of these medications suggest direct central anti-
convulsive and anti-tussive effects for PPIs  [190, 191] .
 Conclusion 
 Gastric acid plays a role in regulating gastric function, 
protects against GI pathogens, facilitates the digestion 
and absorption of certain nutrients and may modulate 
feeding behavior. These properties represent a clear ad-
vantage to individuals on the verge of starvation who 
need to extract every last nutrient from a limited, con-
taminated food supply in order to survive. This is the 
situation in which most humans existed until the very 
recent past and it continues to be the case in many indi-
viduals living in the developing world; however, it is only 
now becoming clear to what extent gastric acid has clini-
cally relevant effects in the developed world. Although 
the absolute risk is low, acid suppression does increase the 
risk of GI infection and this may be of importance in 
community outbreaks, and especially in hospitals and 
nursing homes in the light of increasing virulence of bac-
terial strains such as  C. difficile. Similarly, recent evi-
dence suggests that the effect of acid suppression on cal-
cium absorption increases the risk of hip fracture in at-
risk populations. Long-term follow-up has not found 
evidence that potent acid suppression with PPIs is related 
to increasing rates of esophageal cancer or other malig-
nant diseases; however, this needs to be monitored as pa-
tients embark on an essentially life-long therapy with 
these medications. Finally a better understanding of neu-
ropsychological effects of gastric acid is required. The 
link between gastrointestinal ‘humors’, health and well-
being has a history stretching back to Galen, and there 
surely is more to be understood about the way gastric acid 
affects GI function, feeding behavior and mood.
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